Rising burden of Plasmodium vivax in Mizoram: an emerging threat to malaria elimination in Northeast India Authors: C Vanlalhriata, Pooja Telugu Prakash, Karuppusamy Balasubramani, Lalfakzuala Pautu, Lal Zawmi, Lal Hlunpuii, Rajendra Pilankatta, Nachimuthu Senthil Kumar, Ipsita Pal Bhowmick, Praveen Balabaskaran Nina Published: 2026 ABSTRACT AbstractBackgroundIndia has made tremendous progress in malaria elimination efforts; however, several malaria pockets with high transmission remain that require continuous focus. The Northeast (NE) state of Mizoram, bordering Bangladesh and Myanmar, tops the list for disproportionately contributing to India’s malaria burden. Considered a Plasmodium falciparum-endemic region, this study details the shift in malaria epidemiology from P. falciparum to P. vivax in Mizoram, complicating malaria elimination efforts in an already highly vulnerable setting.MethodsMalaria data for the NE states were obtained from the National Center for Vector Borne Disease Control, while aggregated health center-wise data for Mizoram’s Mamit district (2021–2025) were obtained from the Office of the Chief Medical Officer, Mamit district, Mizoram. Spatiotemporal analyses of malaria cases and environmental variables were performed using ArcGIS 10.4 to identify disease trends, clustering, and high-risk areas.ResultsIn Mizoram, the steep shift in malaria incidence from P. falciparum to P. vivax was noticeable from 2022 onward; from 23% in 2021, P. vivax increased to 47% in 2024 and 42% in 2025. In 2020, Siaha—Mizoram’s southern district bordering Myanmar—reported the first increase in P. vivax infections at the state level. In Mizoram’s western district of Mamit, P. vivax contributed to 68% of the cases in 2025, and among children < 5 years, 86% of the infections were attributed to P. vivax. While P. falciparum transmission coincided with the monsoon season, P. vivax transmission was perennial.ConclusionThe recent surge in Mizoram’s P. vivax cases appears to mirror the epidemiological shift from P. falciparum to P. vivax in bordering Myanmar. It is possible P. vivax parasites from Myanmar could have entered Mizoram through the southern districts of Siaha and Lawngtlai. As several studies in the last decade have reported chloroquine-resistant P. vivax infections in Myanmar, it is imperative that therapeutic efficacy studies are urgently carried out in Mizoram to ascertain the status of CQ-resistant parasites.Keywords: Malaria, Plasmodium vivax, Mizoram, North East India, Spatiotemporal analysis Introduction The malaria situation in India is complex, with varying incidence rates across different states affected by vector diversity, geo-climatic conditions, socio-economic development, and distribution of Plasmodium species. India’s malaria epidemiology in the 1960s was dominated by P. vivax [1]. However, in the 1970s, there was a steady increase in P. falciparum prevalence, driven by increased genetic plasticity, especially in South East Asian parasites, which enabled them to acquire antimalarial resistance and expand much faster [2–4]. By the start of the 21st century, P. falciparum cases became roughly equal to P. vivax, and from 2014, P. falciparum infections experienced a surge until 2016, followed by a downward trend with slight fluctuations, primarily due to species-specific control strategies [5, 6]. On the other hand, P. vivax is still susceptible to most antimalarials [7, 8], and chloroquine (CQ) continues to be the first-line antimalarial across India [9]. Spatiotemporal analysis of national malaria reports from 2007 to 2022 showed a heterogeneous distribution of P. falciparum and P. vivax across the different regions of India—the Central, East, and North-Eastern (NE) states had a high prevalence of P. falciparum with an average of > 1,000 cases per million, while P. vivax, in addition to co-existing with P. falciparum in these malaria-endemic states, was also highly prevalent in the urban centers of India [6]. Over the past decade, India’s sustained efforts to eliminate malaria by 2030—the “Test, Treat, Track” approach, extensive vector control via Indoor Residual Spraying (IRS), distribution of Long-Lasting Insecticidal Nets (LLINs), and the 1-3-7 surveillance model— have resulted in a steep decrease in malaria cases and deaths across most parts of the country [10], and India has formally exited the World Health Organization’s High Burden to High Impact group category in 2023 [11]. As of 2023, 122 out of 650 districts in India reported zero indigenous cases [12]. Despite the substantial progress in malaria case reduction, a few high-burden districts continue to report high caseloads and are a bottleneck to India’s malaria elimination efforts. The important ones are Mamit, Lunglei, and Lawngtlai, the western districts of the NE state of Mizoram, located along the Indo-Bangladesh border [13]. With an Annual Parasite Index (API) of 12.9 in 2024, Mizoram falls under Category 3 (intensified control phase) of the National Framework for Malaria Elimination 2016–2030 [13]. This classification reflects Mizoram’s high transmission intensity and the need for focused research and tailored interventions. Mizoram, situated in the Indo-Burma Biodiversity Hotspot [14], shares international borders with Myanmar and Bangladesh. Despite accounting for only ~ 0.09% of India’s population, Mizoram contributed to 6.6% of the country’s malaria cases in 2024, highlighting a disproportionate malaria burden [13, 15]. The increased and persistent malaria burden could be attributed to multiple factors, including porous international borders, hilly terrain, dense forest cover, monsoon climate, occupational exposure during traditional jhum (shifting) cultivation, and limited understanding of local parasite and vector biology [16]. The health centers in Mizoram’s western districts bordering Bangladesh have consistently reported an annual parasite index (API) of > 10 [16]. It is pertinent to note that these districts share geographical boundaries and environmental conditions with Bangladesh’s Chittagong Hill Tracts (CHT) [16], which contributes to ~ 90% of Bangladesh’s cases [17]. Historically, malaria in Mizoram has been predominated by P. falciparum, accounting for over 80% of cases [16]. However, since 2021, Mizoram has been witnessing a steep increase in P. vivax cases, rising from 1,872 in 2021 to 7,949 in 2024, accounting for 47% of total infections [13]. In addition to Bangladesh, Mizoram shares its borders with Myanmar, where P. vivax has replaced P. falciparum as the dominant parasite [11]. Furthermore, several reports of CQ-resistant P. vivax infections have also been reported in Myanmar [18, 19]. Political unrest in Myanmar borders has resulted in migration of thousands of refugees from the bordering villages of Myanmar to Mizoram [20]. Given the porous border and shared vectors, the risk of importing CQ-resistant parasites from Myanmar into Mizoram cannot be ignored [21, 22]. The rise of P. vivax in Mizoram poses a complex and urgent challenge to malaria elimination efforts in this region. P. vivax’s hypnozoite stages and their ability to relapse, make it harder to detect, treat, and eliminate compared to P. falciparum. For targeted malaria control measures to be implemented, it is imperative to understand the transmission dynamics of P. vivax. To understand the spatiotemporal spread, we have analysed the shifting epidemiology of P. vivax infections at district-level across Mizoram. Furthermore, to capture the heterogeneity of P. vivax risk, we have mapped the clustering of P. vivax cases at the primary health center level in Mamit district, and examined the relationship between environmental factors and P. vivax incidence. Methods Study setting The study district Mamit is an aspirational district of Mizoram, NE India. Mamit is situated in the western part of Mizoram and shares its international border with Bangladesh. The district is characterized by dense forests, hard-to-reach hilly and rugged terrain, and low socio-economic condition. Jhum cultivation is the major occupation of villagers in this region, which increases their risk to malaria. The majority of the healthcare facilities are run by the Government. The public health centers—Health and Wellness Centers (HWC), Primary Health Centers (PHCs), Community Health Centers (CHCs) and district hospitals are the main source for malaria treatment across Mamit and Mizoram. The healthcare facilities follow the standard treatment as per the National Drug Policy on Malaria, which is Artemether-Lumefantrine (ACT-AL) for P. falciparum (artemether: 20–80 mg and lumefantrine:120–480 mg as per age and body weight twice daily for 3 days), Chloroquine for P. vivax (25 mg/kg for 3 days), and ACT-AL for mixed infections of P. falciparum and P. vivax (same as given for P. falciparum). Primaquine is administered for radical cure—0.75 mg/kg on day 02 for P. falciparum and 0.25 mg/kg for 14 days for P. vivax and mixed infections [9]. The Accredited Social Health Activist (ASHA) workers, generally part of the HWC, diagnose suspected febrile malaria patients at their homes through RDT and will prescribe the appropriate antimalarial; in Mamit, a majority of malaria cases are diagnosed and treated this way. As of now, Glucose-6-phosphate dehydrogenase (G6PD) screening is not carried out in the Mamit district or in Mizoram. Study design and data source The present study utilized an ecological design to investigate the spatiotemporal distribution of malaria in Mizoram using reported malaria cases. State-wise malaria cases for NE Indian states (2024) and year-wise malaria cases for Mizoram from 2010 to 2025 were obtained from the official website of the National Center for Vector Borne Disease Control (NCVBDC). For the Mamit district (2021–2025), anonymized month-wise aggregated malaria data from PHCs, CHCs, and district hospital were obtained from the Office of the Chief Medical Officer (CMO), Mamit district. The data also included age- and, gender- stratified month-wise malaria caseload for 2025, as done across India. Malaria cases in Mizoram are diagnosed by microscopy and Government-approved bivalent RDT (HRP2 for P. falciparum and LDH for P. vivax). The environmental parameters such as temperature, rainfall, humidity, and elevation were obtained from the NASA Power [23] and Earth Data [24] portals. Spatial analysis The state and district-level malaria cases were added to the spatial database and prepared as thematic layers with located bar diagrams. Health facility–wise malaria cases of Mamit district were geocoded and linked as attributes to their respective facility locations to prepare proportional dot maps. Choropleth mapping techniques were used to depict the geographic distribution of environmental parameters and intensity of malaria burden across the study area over time. All spatial visualization and analysis were performed using ArcGIS version 10.4, and MS Excel sheet. Results Malaria distribution across North-East India in 2024 shows noticeable spatial heterogeneity, with Mizoram reporting the highest burden among all the northeastern states (Fig. 1). Spatial distribution of malaria in North East India and temporal trend of malaria cases in Mizoram. (A) Location map of North East Indian states; (B) State-wise malaria cases in North East India in 2024; (C) Malaria trend with the proportions of P. falciparum (pale blue) and P. vivax (red) in Mizoram from 2010 to 2025. Source: NCVBDC (https://ncvbdc.mohfw.gov.in) Temporal analysis (2010–2025) shows a steady increase in cases from 2011 to 2015, followed by a sharp decline for the next three years, followed by a moderate increase until 2021 (Fig. 1C). Since 2022, malaria cases have risen again, along with an increasing proportion of P. vivax infections. From 23% (1,872 cases) in 2021, the P. vivax cases have increased steeply to 47% (7,949 cases) in 2024 and 42% (3,735 cases) in 2025. From 2019 to 2024, a highly heterogeneous distribution of malaria cases across Mizoram’s districts was seen (Fig. 2). Malaria endemicity is high in the western (Mamit and Lunglei), south-western (Lawngtlai), and southern (Siaha) districts. Mamit and Lunglei share international borders with Bangladesh, Siaha with Myanmar, while Lawngtlai shares its western and southern borders with Bangladesh and Myanmar, respectively. Malaria caseload steeply decreases in the central (Aizawl and Serchhip), northern (Kolasib), and eastern (Champhai) districts of Mizoram. Even though P. vivax cases have increased across all districts of Mizoram, the early rise, from 2020 onward, was notable in Siaha, Lawngtlai, and Lunglei. Compared to 2019, cases increased 3.7-fold in Siaha (from 61 to 223), 2.9-fold in Lawngtlai (from 198 to 583), and 2.5-fold in Lunglei (from 127 to 326), respectively in 2020. In 2024, P. vivax accounted for 80% (1286 cases) of the malaria infections in Siaha. As of 2024, the proportion of P. vivax cases in the central and eastern districts of Mizoram has exceeded P. falciparum. Distribution of malaria cases in Mizoram from 2019 to 2024. The color gradient represents the cumulative malaria cases in the districts. The bar chart of each district illustrates the year-wise distribution of P. falciparum (pale blue), P. vivax (red), and mixed infections (blue) in Mizoram. Source: NCVBDC (https://ncvbdc.mohfw.gov.in) Siaha district, located in the southernmost tip of Mizoram bordering Myanmar’s Chin State displays strong environmental continuity across all six parameters with the Chin state of Myanmar (Fig. 3). All districts in Mizoram experience maximum temperatures in the range of 34–36 °C, minimum temperatures around 12–15 °C, and an overall temperature range of approximately 15–18 °C, reflecting moderate seasonal fluctuation. Siaha displays characteristics of a subtropical highland environment situated at 500–1,000 m elevation, with an annual rainfall of 900–1,800 mm, and a humidity of ~ 65–70%, indicating a warm-humid environment. The adjacent Chin State shares these climatic characteristics in the bordering areas; however, as we move eastward into Myanmar, the elevation rises higher to 1,200 m and above, producing slightly cooler weather with minimum temperatures reaching below 12 °C and a wider seasonal temperature range. However, towards the western part of Mizoram, including Mamit district, a more favorable environmental profile for malaria transmission is observed. The region’s elevation is below 800 m and experiences higher annual rainfall, exceeding up to 2100 mm. Humidity in the west is also higher, consistently around 70–75%. These lower, warmer, and more humid conditions provide an ideal ecological niche for vector breeding in the southern and western parts of Mizoram. Spatial distribution of average (a) Maximum Temperature, (b) Minimum Temperature, (c) Temperature Range, (d) Rainfall, (e) Relative Humidity, and (f) Elevation. The legend of each figure is given separately. The darker shades of color ramp in figures represent relatively higher values. The international borders and district boundaries are presented in light grey and Siaha district is highlighted with dark line The spatiotemporal distribution of malaria cases in Mamit district from 2021 to 2025 shows a clear increase in transmission intensity and a shift in parasite epidemiology (Fig. 4). In 2021, malaria cases were comparatively fewer and spatially scattered, with several health centers reporting no cases; among the reported, P. falciparum was the predominant species. In 2022, malaria transmission expanded in magnitude, as indicated by larger case clusters across multiple health centers, particularly in the western and southern parts of the district. Even though P. falciparum remained the dominant species, the proportion of P. vivax increased at several centers. A marked escalation was observed in 2023—P. vivax contributed substantially to the total caseload, with several centers showing comparable or higher P. vivax proportions than P. falciparum. This pattern persisted into 2024 and 2025, characterized by large, spatially clustered outbreaks and a clear shift towards P. vivax dominance across all health centers. Even though the number of malaria cases reduced across many PHCs, the proportion of P. vivax cases increased. The southern and western foci, including Marpara, Phuldungsei, W Phaileng, and Kawrtethawveng PHCs, reported high P. vivax caseloads in 2025. Spatiotemporal dynamics and shift in malaria transmission in PHCs of Mamit district from 2021 to 2025. The size of the dot represents a relative case load with the proportions of P. falciparum (sky blue) and P. vivax (red). The high case load centers are labeled which are located close to the Indo-Bangladesh border The month-wise demographic distribution of malaria cases in 2025 at Mamit district is shown in Fig. 5. In 2025, P. vivax accounted for 68% of the total malaria cases at Mamit. Age-wise distribution (Fig. 5A) shows that malaria predominantly affected adolescents, with the highest case load observed among those aged 15 + years. Even though the absolute number of cases was lower in children aged 0–4 years, a substantial proportion of P. vivax infections (86.2%) occurred in this age group. Sex-wise analysis (Fig. 5B) revealed a higher burden of P. vivax infections in males (58.6%) than in females (41.4%). Demographic and seasonal distribution of malaria cases in Mamit district in the year 2025, with age-wise (A) and sex-wise (B) distribution of malaria cases by Plasmodium species; and month-wise distribution (C) of malaria cases across age groups and Plasmodium species The month-wise distribution (Fig. 5C) demonstrates clear seasonality in malaria transmission, especially for P. falciparum, with peaks during the monsoon months from May to August. In contrast, P. vivax cases persisted year-round, indicating a perennial transmission pattern. P. vivax consistently contributed the largest share of cases in every age group throughout the year. Even though fewer malaria cases were reported in absolute numbers during the dry months, P. vivax predominated. Discussion Historically, the malaria situation in Mizoram was dominated by P. falciparum (> 80%), but in recent years, the state is witnessing a steep increase in P. vivax infections. For the first time in over a quarter century, P. vivax has exceeded 45% of the total malaria infections in 2024 [13]. Mizoram’s epidemiological shift toward P. vivax complicates malaria prevention and control in an already challenging geographical setting—poor roads and logistics, lack of infrastructure facilities, thick forest cover, and hard-to-access underserved communities. Asymptomatic and low-density P. vivax infections, along with their ability to stay dormant as persistent hypnozoite liver stages, complicate prompt diagnosis and treatment, and their control [25]. In the past, P. vivax was often neglected as a “benign” infection, but recent data highlights the global health threat posed by the parasite, which triggers lethal physiological responses even at low parasitemia [26]. Over the last two decades, multiple studies have shown fatal vivax malaria in India—a pooled prevalence of 29.3% severe P. vivax cases and a mortality rate of 0–12.9% were observed from 162 studies [27]. Evidence from large-scale hospital-based studies shows severity and mortality of P. vivax infections are similar to that of P. falciparum [28, 29]. Young children and pregnant women are highly vulnerable and experience adverse clinical outcomes—severe anemia affecting health and school performance, and maternal anemia resulting in poor pregnancy outcomes, respectively [30]. Spatio-temporal analyses show a steep P. vivax increase in the districts of Siaha and Lawngtlai from 2020 onwards. Our previous sub-center wise analysis of malaria cases across Mizoram also showed the steep increase in P. vivax cases in 2020 at Siaha district [31]. The reasons for this increase are likely multifactorial—ecological suitability, cross-border transmission, emergence of autochthonous resistance, and/or improper uptake or metabolism of primaquine. Improper uptake is less likely as the villagers in Mizoram have high awareness about the disease and complete the drug regimen promptly [32]. The malaria-endemic Chin State of Myanmar shares its border with the Siaha and Lawngtlai districts of Mizoram, and the Bandarban district, part of malaria-endemic Bangladesh’s CHT [33]. In Myanmar, from 2019 to 2023, P. vivax caseloads has increased six-fold; in 2024, P. vivax accounted for 91% (173018) of total indigenous malaria cases [11, 34]. Following Myanmar’s 2021 military coup, malaria incidence has doubled in Chin State, with 40% P. vivax and 24% mixed (P. vivax + P. falciparum) infections [35]. Malaria emergence has been reported in the non-malaria-endemic Falam Township, bordering the Siaha district of Mizoram, along with an increase in malaria incidence in already endemic Paletwa, Kanpetlet, Mindat, and Thantlang townships of Myanmar [35]. A multicentric therapeutic efficacy study has documented low levels of late parasitological failures to CQ treatment in the Kyauktaw township of western Myanmar, indicating geographical heterogeneity [18]. Recent studies from Myanmar and the Greater Mekong Subregion continue to report sporadic late recurrences, suggesting focal, geographically heterogeneous, and evolving susceptibility in P. vivax populations [18, 36]. There are reports of high frequencies of mutations in pvmdr1 (Y976F, F1076L), and pvcrt-o (AAG insertion)—associated with reduced chloroquine susceptibility—and pvdhfr and pvdhps—linked to antifolate resistance indicating sustained drug selection pressure in P. vivax across Myanmar [19, 37]. However, resistance-associated markers alone cannot confirm clinical resistance and must be interpreted along with therapeutic efficacy studies, which have shown varying levels of CQ susceptibility in Myanmar from the 1990s [38–41]. In contrast, reduced effectiveness of primaquine is known to be attributed to host CYP2D6 polymorphisms and dosing variability rather than parasite resistance [42, 43]. A study in Myanmar showed a 25.6% recurrence rate after low-dose primaquine treatment, which was strongly linked with impaired CYP2D6 enzyme activity [44]. Primaquine metabolism with CYP2D6 polymorphisms is not studied in India so far. Historically, drug-resistant parasites in Northeast India have been thought to originate in Southeast Asia, entering the region via porous borders with Myanmar [33]. The political situation in Myanmar has resulted in an influx of refugees from Myanmar (Chin communities) to different villages of Mizoram’s Champhai, Saitual, Siaha, and Lunglei districts has been reported [45]. Due to the presence of ethnically related Mizo communities on both sides of the Indo-Myanmar border, individuals from both countries regularly travel across the border region for family visits, social interactions, markets, and occupational activities [46, 47], which may enable undetected parasite flow. A recent kelch13 functional study reveal potential for high level artemisinin resistance in P. falciparum from CHT of Bangladesh [48]. Hence, there is an urgent need for border-focused malaria control in Mizoram, which should include active molecular surveillance for detection of low-density and submicroscopic Plasmodium infections, and continuous therapeutic efficacy studies for early detection of drug-resistant parasites in the high-risk international border districts of Siaha, Lawngtlai, Champhai, and Lunglei. Compared to other districts, the reason for the steep increase in P. vivax cases in Mamit and Lunglei (bordering Bangladesh), and Lawngtlai (bordering Bangladesh and Myanmar) is the ecological niche—favorable environmental conditions, forested habitats, foothill streams, and changing land-use patterns—that strongly favor vector breeding and intense malaria transmission [16, 22, 49, 50]. As seen in Mizoram, P. vivax cases have also increased steeply in Tripura, especially in the districts bordering Bangladesh’s CHT [13], underscoring the threat P. vivax poses to malaria elimination efforts in North-East India. Political unrest and instability in the international border region has made research and surveillance in these neighbouring areas difficult. Mizoram, bordering Myanmar and Bangladesh, provides a unique setting to study malaria epidemiology, including the evolution of drug-resistant parasites. A significant proportion of asymptomatic P. vivax infections was reported in community settings of Dhalai district, Tripura [51]. The increase in the clinical cases of P. vivax could be preceded or sustained by the asymptomatic P. vivax infections observed in the community. Even though isolated reports of CQ resistance have been reported in India [7], its overall prevalence remains low, supporting the continued use of CQ as the first-line antimalarial against P. vivax. So far, no reports of CQ resistance have been reported from NE India. However, the recent increase in P. vivax cases in Mizoram underscores the urgent need for therapeutic efficacy studies in this region. A key finding of our study is that P. vivax infections are disproportionately high (86.2%) among children under 5 years, and the 5–14-year group carried the highest caseload. These age-specific patterns are consistent with broader evidence that P. vivax primarily affects younger age groups in endemic settings [52–54], possibly due to children not having developed clinical immunity, and the parasite’s relapse dynamics increase cumulative exposure over time [55]. However, acquisition of clinical immunity is faster in P. vivax when compared to P. falciparum [52, 56]. An increased P. vivax burden among males could be attributed to increased exposure to mosquitoes through outdoor activities, as observed in other parts of India [57]. Another interesting observation in this study is the perennial transmission pattern of P. vivax, unlike the seasonal pattern of P. falciparum. While hypnozoite relapse in P. vivax, weeks to months after the primary infection, is often used as a cause to explain such patterns [58], relapse periodicity has been known to adapt with local vector ecology, typically synchronizing with periods of Anopheles abundance [59]. This is consistent with the classical hypothesis proposed by Lysenko et al. (1977), which suggests that relapse phenotypes are shaped by ecological conditions and vector availability [60]. In this context, the year-round presence of P. vivax in our study area may not be solely attributable to relapse. Entomological evidence from the NE states highlights the emergence of secondary anopheline species that sustain malaria transmission, particularly during dry seasons when primary vector populations are low [61–63]. Along with An. minimus—the dominant malaria vector, An. philipinensis, An. nivipes, An. jamesii and An. jeyporiensis have been recently reported in Mizoram [64]. Understanding the role of secondary vectors and incorporating them into local surveillance and control strategies is crucial for achieving sustained malaria control in Mizoram and NE India. With P. vivax establishing itself as the predominant parasite in Mizoram, its successful control and eventual eradication requires elimination of the hypnozoite reservoirs. As the hypnozoites cannot be diagnosed by RDT or microscopy, presumptive treatment with PQ, the hypnozoitocidal drug, is the preferred approach. Studies in temperate zones have shown the mass drug administration (MDA) of PQ to be very efficient in reducing and even eradicating P. vivax [65–67]. Even in the subtropical setting of Myanmar, PQ-MDA was shown to be very effective in reducing clinical and subclinical P. vivax infections in a low-endemic setting [68]. However, prior to initiating MDA programs, it is necessary to estimate the prevalence of G6PD deficiency in this region; PQ can trigger haemolysis in G6PD deficient individuals [69]. In Myanmar, the prevalence of G6PD deficiency varies from 10 to 20% [70]. A preliminary study in Mizoram found 17.5% G6PD deficiency among Mizo tribes [71]. Prevalence of G6PD deficiency was documented in NE Indian states, including Mizoram, where G6PD-Mahidol—the most common variant in Myanmar—was found. Limitations of the study This study has several limitations that need consideration. First, the analysis was based on routinely passive surveillance data from public health centers, which may not be comprehensive. As malaria surveillance in Mizoram is predominantly based on passive case detection of febrile patients, undiagnosed asymptomatic community infections were not captured, potentially underestimating the true malaria burden, particularly for P. vivax. Second, more than 90% of malaria diagnoses were based on bivalent HRP-2/pLDH, which, although practical and convenient in remote settings, does not detect other malaria parasites, has lower sensitivity for low-density infections, and may misclassify species in mixed or low-parasitemia infections, which could affect species-specific estimates. Even though P. vivax has been steadily increasing in Mizoram for the past five years, the month-wise age- and sex-stratified data of P. vivax were available only from August 2024; a longer window would have helped interpret P. vivax distribution with confidence and is a major limitation of the study. Third, the environmental analysis in our study does not show causal inference due to limited temporal data. Cross-border malaria movement from Myanmar and Bangladesh is likely to influence transmission dynamics in Mizoram, but such importation could not be directly interpreted due to the absence of cross-border malaria surveillance or migration data. Despite these limitations, the study provides important pragmatic relevant information on the emerging dominance of P. vivax and its spatial heterogeneity in Mizoram. Furthermore, spatial mapping of P. vivax infections at the sub-center level across all Mizoram’s districts would have given deeper insights into the environmental conditions and spatio-temporal distribution of P. vivax transmission. Conclusion Situated at the intersection of the high-risk malaria zones of Myanmar and Bangladesh, Mizoram offers a strategic vantage point for studying malaria epidemiology and the evolution of drug resistance. The recent rise in P. vivax cases, particularly in the bordering districts, will complicate the malaria elimination efforts in India, Bangladesh, and Myanmar. In addition to current malaria control efforts, successful disruption of P. vivax transmission in Mizoram requires molecular screening for asymptomatic and submicroscopic infections, continuous therapeutic efficacy studies for Plasmodium spp., strengthening vector control strategies to continuously monitor the emergence of new vectors, evaluating the efficacy of vector control practices, identification of insecticide-resistant vectors, improving both active and passive surveillance in the bordering villages, and careful implementation of radical cure strategies concomitant with G6PD screening. Without rapid, adaptive, and region-specific interventions, malaria elimination in North-East India will be challenging, with far-reaching implications affecting malaria control in South-East Asia. Acknowledgements We acknowledge the National Center for Vector-Borne Disease Control, India, and the Ministry of Health and Family Welfare, Government of Mizoram, for the data. We also thank the health workers in the Mamit district for their assistance with data collection. Abbreviations Northeast Chloroquine Chittagong Hill Tracts Annual parasite index National Center for Vector Borne Disease Control Primary health centers Urban health centers Community health centers Primaquine Mass drug administration Glucose-6-phosphate dehydrogenase Author contributions Conceptualization: PBN. Data curation: CV, PTP. Methodology: KB, SS. Formal analysis: KB, SS. Investigation: LP, LZ, LH. Writing first draft: CV, PTP. Review and finalization of draft: All authors. Supervision: PBN. Funding acquisition: None. Funding No funding was received for this research. Data availability The state and district-wise datasets analyzed during the current study are available in the NCVBDC website (https://ncvbdc.mohfw.gov.in). Mizoram health center-wise data are not publicly available; to obtain access to the restricted data, a formal proposal outlining the research intent, ethical approval from the host institute, and a formal request for datasets should be made to the state program officer, NVBDCP, Mizoram (nvbdcp_mizoram@yahoo.co.in), and Chief Medical Officer, Mamit, Mizoram (Email ID: cmomamit@gmail.com). Declarations Ethics approval and consent to participate The “waiver of consent” for the use of secondary datasets for this study was approved by the Institutional Human Ethics Committee (IHEC) of Central University of Kerala. The waiver was granted on the basis that all malaria data obtained were anonymized/aggregated. This study followed the ICMR National Ethical Guidelines for Biomedical and Health Research (2017). Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. C. Vanlalhriata and Pooja Telugu Prakash contributed equally to this work. Contributor Information Karuppusamy Balasubramani, Email: geobalas@cutn.ac.in. Praveen Balabaskaran Nina, Email: praveen.nina@cukerala.ac.in. References Associated Data Data Availability Statement The state and district-wise datasets analyzed during the current study are available in the NCVBDC website (https://ncvbdc.mohfw.gov.in). Mizoram health center-wise data are not publicly available; to obtain access to the restricted data, a formal proposal outlining the research intent, ethical approval from the host institute, and a formal request for datasets should be made to the state program officer, NVBDCP, Mizoram (nvbdcp_mizoram@yahoo.co.in), and Chief Medical Officer, Mamit, Mizoram (Email ID: cmomamit@gmail.com).